Tenderwize
Wróć do wyszukiwania

Non-exclusive pharmaceutical rebate agreement Brinzolamid/Timolol

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Dec 31, 2026 · 126 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Brinzolamid/Timolol (amtlicher ATC-Code: S01ED67)

40/100

Ocena szansy

Needs reviewLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

40 / 100

Złożoność

30 / 100

Czynniki ryzyka

No minimum purchase quantities are guaranteed. Actual demand depends on patient numbers, prescribing habits, and pharma...

The buyer may terminate the Open-House procedure early if exclusive agreements are concluded, which could happen 8-12 m...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Conclude non-exclusive rebate agreements for the pharmaceutical product Brinzolamid/Timolol (eye drops).
  • Supply of the product to pharmacies in the regions of Saxony and Thuringia (Germany) as prescribed by physicians.
Pokaż pełne podsumowanie

This is an Open-House model (non-exclusive) for concluding pharmaceutical rebate agreements for the active substance Brinzolamid/Timolol (ATC code S01ED67) under §130a Abs. 8 SGB V. The procedure is open to all interested pharmaceutical companies that meet participation requirements. No individual negotiations, no exclusivity, and no guaranteed minimum purchase quantities. The agreement ends no later than 31.12.2026, but may terminate earlier if exclusive agreements are concluded. Participation requests can be submitted from 03.12.2024, with multiple submission deadlines as per the document 'Einreichungsfristen'. Communication and submission are electronic via DTVP. The buyer is AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen.

Ryzyka

No minimum purchase quantities are guaranteed. Actual demand depends on patient numbers, prescribing habits, and pharma...

The buyer may terminate the Open-House procedure early if exclusive agreements are concluded, which could happen 8-12 m...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur within the meaning of §4 Abs. 18 AMG.

Eligibility

  • Submission of a declaration on absence of exclusion grounds (Anlage 'Eigenerklärung zum Nichtvorliegen von Ausschlussgründen').

Administrative

  • Declaration regarding EU Russia sanctions (Anlage 'Eigenerklärung Russlandsanktionen').

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

No award criteria specified; this is an Open-House model, not a competitive award.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Non-exclusive pharmaceutical rebate agreement Brinzolamid/Timolol

Single lot covering the entire scope: non-exclusive rebate agreements for Brinzolamid/Timolol. No lot-specific details beyond the overall description.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Dec 2024 - Dec 2026

Kategoria

Pharmaceutical products

Kryteria udzielenia

No award criteria specified; this is an Open-House model, not a competitive award.

Termin

Deadline Dec 31, 2026

Szczegóły zamówienia

Data publikacji
10 Nov 2024
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
683594-2024

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3